Omeprazole	other-medical
reacts	O
with	O
cysteine	O
813	O
and	O
892	O
.	O

Thoracentesis	other-medical
and	O
an	O
indwelling	other-medical
catheter	other-medical
for	O
use	O
at	O
home	O
is	O
generally	O
used	O
to	O
drain	O
the	O
chylothorax	O
.	O

Home	other-medical
hemodialysis	other-medical
has	O
become	O
rare	O
because	O
of	O
its	O
disadvantages	O
.	O

Pfizer	O
UK	O
was	O
presented	O
with	O
the	O
Queen	O
's	O
Award	O
for	O
Technological	O
Achievement	O
in	O
1979	O
,	O
in	O
recognition	O
of	O
the	O
outstanding	O
contribution	O
made	O
to	O
tropical	O
medicine	O
by	O
the	O
medicine	O
Mansil	other-medical
(	O
oxamniquine	O
)	O
,	O
which	O
had	O
been	O
developed	O
at	O
the	O
Sandwich	O
site	O
.	O

Prophylactic	O
use	O
of	O
both	O
omeprazole	other-medical
and	O
H2	other-medical
antagonists	other-medical
such	O
as	O
ranitidine	other-medical
,	O
cimetidine	other-medical
,	O
and	O
famotidine	other-medical
can	O
be	O
used	O
to	O
help	O
prevent	O
gastric	O
ulcer	O
formation	O
when	O
the	O
horse	O
will	O
be	O
placed	O
into	O
a	O
stressful	O
situation	O
,	O
such	O
as	O
travel	O
or	O
showing	O
.	O

Brand	O
names	O
of	O
MPA	other-medical
in	O
combination	O
with	O
CEEs	other-medical
as	O
oral	O
tablets	O
in	O
different	O
countries	O
include	O
Prempro	other-medical
,	O
Premphase	other-medical
,	O
Premique	other-medical
,	O
Premia	other-medical
,	O
and	O
Premelle	other-medical
.	O

Frequency	O
of	O
treatment-emergent	O
sexual	O
dysfunction	O
were	O
similar	O
for	O
duloxetine	other-medical
and	O
SSRIs	other-medical
when	O
compared	O
in	O
a	O
6-month	O
observational	O
study	O
in	O
depressed	O
patients	O
.	O

Although	O
gabapentin	other-medical
and	O
pregabalin	other-medical
possess	O
low	O
abuse	O
potential	O
,	O
these	O
drugs	O
can	O
cause	O
physical	O
dependence	O
over	O
the	O
course	O
of	O
normal	O
treatment	O
,	O
and	O
certain	O
patients	O
may	O
become	O
psychologically	O
dependent	O
as	O
well	O
.	O

Pharmacological	O
treatment	O
using	O
a	O
highly-specific	O
ALK	O
inhibitor	O
corrected	O
all	O
these	O
defects	O
in	O
flies	O
and	O
this	O
therapeutic	O
approach	O
was	O
later	O
successfully	O
validated	O
in	O
a	O
preclinical	O
mouse	O
model	O
of	O
NF1	O
by	O
treating	O
mice	O
with	O
Alectinib	other-medical
,	O
suggesting	O
it	O
represents	O
a	O
promising	O
therapeutic	O
target	O
.	O

In	O
general	O
,	O
short-term	O
therapy	O
is	O
more	O
effective	O
than	O
long-term	O
therapy	O
with	O
clonazepam	other-medical
for	O
the	O
treatment	O
of	O
epilepsy	O
.	O

Lysergic	other-medical
acid	other-medical
diethylamide	other-medical
(	O
LSD	other-medical
)	O
,	O
also	O
known	O
colloquially	O
as	O
acid	O
,	O
is	O
a	O
hallucinogenic	O
drug	O
.	O

Abemaciclib	other-medical
(	O
LY2835219	other-medical
)	O
(	O
trade	O
name	O
Verzenio	other-medical
)	O
acts	O
as	O
a	O
selective	O
inhibitor	O
for	O
CDK4	O
and	O
CDK6	O
.	O

Radiography	O
and	O
NMR	other-medical
imaging	O
of	O
the	O
skull	O
can	O
also	O
be	O
utilised	O
.	O

This	O
meant	O
that	O
in	O
contrast	O
to	O
flumazenil	other-medical
,	O
which	O
is	O
ineffective	O
at	O
treating	O
alcohol	O
overdoses	O
,	O
Ro15-4513	other-medical
showed	O
potential	O
as	O
a	O
useful	O
alcohol	O
antidote	O
.	O

It	O
is	O
both	O
a	O
cranial	O
and	O
a	O
focal	O
dystonia	other-medical
.	O

Its	O
plasma	O
half-life	O
is	O
about	O
30	O
hours	O
when	O
it	O
is	O
given	O
as	O
single	O
dose	O
,	O
but	O
it	O
is	O
a	O
strong	O
inducer	other-medical
of	other-medical
hepatic	other-medical
enzymes	other-medical
and	O
the	O
plasma	O
half-life	O
shortens	O
to	O
about	O
15	O
hours	O
when	O
it	O
is	O
given	O
repeatedly	O
.	O

It	O
may	O
also	O
cause	O
interactions	O
with	O
anesthetics	O
,	O
so	O
its	O
use	O
should	O
be	O
related	O
to	O
the	O
veterinarian	O
if	O
the	O
animal	O
is	O
going	O
into	O
surgery	O
,	O
and	O
it	O
decreases	O
the	O
kidneys	O
'	O
ability	O
to	O
excrete	O
aspirin	other-medical
,	O
so	O
dosages	O
will	O
need	O
to	O
be	O
adjusted	O
if	O
combined	O
with	O
that	O
drug	O
.	O

Cirrhosis	O
is	O
a	O
late	O
stage	O
of	O
serious	O
liver	O
disease	O
marked	O
by	O
inflammation	other-medical
(	O
swelling	other-medical
)	O
,	O
fibrosis	other-medical
(	O
cellular	other-medical
hardening	other-medical
)	O
and	O
damaged	other-medical
membranes	other-medical
preventing	O
detoxification	O
of	O
chemicals	O
in	O
the	O
body	O
,	O
ending	O
in	O
scarring	other-medical
and	O
necrosis	other-medical
(	O
cell	other-medical
death	other-medical
)	O
.	O

However	O
,	O
there	O
is	O
little	O
evidence	O
for	O
a	O
specific	O
diagnosable	O
MDMA	other-medical
dependence	O
syndrome	O
because	O
MDMA	other-medical
is	O
typically	O
used	O
relatively	O
infrequently	O
.	O

Aspirin	other-medical
increases	O
prothrombin	O
time	O
and	O
can	O
result	O
in	O
post-operative	O
complications	O
,	O
such	O
as	O
excessive	O
bleeding	O
.	O

Treponema	other-medical
pallidum	other-medical
particle	other-medical
agglutination	other-medical
assay	other-medical
(	O
TP-PA	other-medical
)	O
and	O
the	O
Toluidine	other-medical
red	other-medical
unheated	other-medical
serum	other-medical
test	other-medical
(	O
TRUST	other-medical
)	O
,	O
which	O
may	O
be	O
used	O
to	O
confirm	O
a	O
positive	O
VDRL	other-medical
result	O
,	O
are	O
more	O
specific	O
for	O
syphilis	O
than	O
non-treponemal	O
tests	O
and	O
in	O
the	O
presence	O
of	O
a	O
positive	O
test	O
,	O
more	O
likely	O
indicate	O
active	O
infection	O
.	O

This	O
technique	O
,	O
combined	O
with	O
PET	other-medical
imaging	other-medical
,	O
is	O
used	O
to	O
image	O
areas	O
of	O
plaque	O
deposits	O
in	O
those	O
with	O
Alzheimer	O
's	O
.	O

They	O
are	O
rethinking	O
chemotherapy	other-medical
because	O
of	O
the	O
antiangiogenic	O
effects	O
of	O
low	O
dose	O
chemotherapy	other-medical
given	O
on	O
a	O
more	O
frequent	O
basis	O
than	O
conventional	O
chemotherapy	other-medical
.	O

Treatments	O
(	O
both	O
preventive	O
and	O
therapeutic	O
)	O
available	O
are	O
pressure	other-medical
therapy	other-medical
,	O
silicone	other-medical
gel	other-medical
sheeting	other-medical
,	O
intra-lesional	other-medical
triamcinolone	other-medical
acetonide	other-medical
(	O
TAC	other-medical
)	O
,	O
cryosurgery	other-medical
(	O
freezing	other-medical
)	O
,	O
radiation	other-medical
,	O
laser	other-medical
therapy	other-medical
(	O
PDL	other-medical
)	O
,	O
IFN	other-medical
,	O
5-FU	other-medical
and	O
surgical	other-medical
excision	other-medical
as	O
well	O
as	O
a	O
multitude	other-medical
of	other-medical
extracts	other-medical
and	O
topical	other-medical
agents	other-medical
.	O

On	O
29	O
June	O
1888	O
,	O
he	O
performed	O
the	O
first	O
appendicectomy	other-medical
in	O
England	O
.	O

5-ARIs	other-medical
are	O
sometimes	O
used	O
as	O
antiandrogens	O
in	O
feminizing	O
hormone	O
therapy	O
for	O
transgender	O
women	O
to	O
help	O
reduce	O
body	O
hair	O
growth	O
and	O
scalp	O
hair	O
loss	O
.	O

2C-T	other-medical
(	O
or	O
4-methylthio-2,5-DMPEA	other-medical
)	O
is	O
a	O
psychedelic	O
and	O
hallucinogenic	O
drug	O
of	O
the	O
2C	O
family	O
.	O

Colchicine	other-medical
in	O
combination	O
with	O
probenecid	other-medical
has	O
been	O
FDA	O
-approved	O
prior	O
to	O
1982	O
.	O

Prodine	other-medical
(	O
trade	O
names	O
Prisilidine	other-medical
and	O
Nisentil	other-medical
)	O
is	O
an	O
opioid	O
analgesic	O
that	O
is	O
an	O
analog	O
of	O
pethidine	other-medical
(	O
meperidine	other-medical
)	O
.	O

Aromatase	O
inhibitors	O
can	O
help	O
to	O
prevent	O
the	O
estrogenic	O
activity	O
of	O
testosterone	other-medical
enanthate	other-medical
in	O
the	O
body	O
.	O

Despite	O
this	O
,	O
heroin	other-medical
users	O
in	O
Australia	O
are	O
more	O
likely	O
to	O
fail	O
in	O
their	O
attempts	O
to	O
quit	O
abusing	O
the	O
substance	O
than	O
any	O
other	O
illicit	O
drug	O
.	O

Bioavailability	O
:	O
Since	O
2013	O
a	O
company	O
named	O
Amorphical	O
Ltd	O
.	O
sells	O
an	O
ACC	other-medical
dietary	O
supplement	O
.	O

SSRI	other-medical
s	O
became	O
known	O
as	O
``	O
novel	O
antidepressants	O
``	O
along	O
with	O
other	O
newer	O
drugs	O
such	O
as	O
SNRIs	other-medical
and	O
NRIs	other-medical
with	O
various	O
selective	O
effects	O
.	O

Gherasim	O
tested	O
positive	O
for	O
anabolic	other-medical
steroids	other-medical
at	O
the	O
Amsterdam	O
Marathon	O
in	O
2002	O
and	O
received	O
a	O
two-year	O
doping	O
ban	O
.	O

A	O
high	O
proportion	O
of	O
bites—five	O
out	O
of	O
eight	O
recorded	O
cases—from	O
the	O
northern	O
tree-dwelling	O
funnel-web	O
spider	O
result	O
in	O
severe	O
symptoms	O
of	O
envenomation	other-medical
.	O

This	O
is	O
much	O
more	O
invasive	O
than	O
angioplasty	other-medical
.	O

The	O
patient	O
took	O
diclofenac	other-medical
75	O
mg	O
1	O
to	O
2	O
hours	O
prior	O
to	O
sexual	O
activity	O
with	O
orgasm	O
,	O
and	O
continued	O
twice	O
daily	O
for	O
24	O
to	O
48	O
hours	O
.	O

In	O
experiments	O
on	O
mice	O
,	O
eglumegad	other-medical
was	O
found	O
to	O
be	O
as	O
effective	O
as	O
diazepam	other-medical
for	O
treating	O
anxiety	O
symptoms	O
in	O
several	O
standard	O
tests	O
,	O
but	O
without	O
producing	O
any	O
of	O
the	O
negative	O
side	O
effects	O
of	O
diazepam	other-medical
such	O
as	O
sedation	O
and	O
memory	O
impairment	O
.	O

Triptans	other-medical
are	O
therefore	O
often	O
preferred	O
treatment	O
in	O
migraine	O
.	O

Charlotte	O
's	O
Web	O
was	O
developed	O
in	O
2011	O
by	O
the	O
Stanley	O
brothers	O
(	O
Joel	O
,	O
Jesse	O
,	O
Jon	O
,	O
Jordan	O
,	O
Jared	O
and	O
Josh	O
)	O
through	O
crossbreeding	O
a	O
strain	O
of	O
marijuana	other-medical
with	O
industrial	O
hemp	O
.	O

Rehabilitation	other-medical
robotics	other-medical
is	O
a	O
new	O
frontier	O
for	O
neurological	O
rehabilitation	O
treatments	O
.	O

Another	O
Cochrane	O
Investigation	O
has	O
found	O
post-operative	other-medical
pain	other-medical
is	O
effectively	O
managed	O
with	O
either	O
ibuprofen	other-medical
,	O
or	O
ibuprofen	other-medical
in	O
combination	O
with	O
acetaminophen	other-medical
.	O

The	O
word	O
dystonia	other-medical
describes	O
abnormal	O
involuntary	O
sustained	O
muscle	other-medical
contractions	other-medical
and	O
spasms	other-medical
.	O

The	O
monoclonal	O
antibody	O
farletuzumab	other-medical
is	O
being	O
researched	O
as	O
an	O
adjuvant	O
to	O
traditional	O
chemotherapy	O
.	O

Day	O
1	O
:	O
Oxaliplatin	other-medical
85	O
mg/m2	O
intravenous	O
(	O
IV	O
)	O
infusion	O
in	O
250-500	O
mL	O
D5W	O
and	O
leucovorin	O
200	O
mg/m2	O
IV	O
infusion	O
in	O
D5W	O
administered	O
concurrently	O
over	O
120	O
minutes	O
in	O
separate	O
bags	O
using	O
a	O
Y-line	O
,	O
followed	O
by	O
fluorouracil	other-medical
(	O
5-FU	other-medical
)	O
400	O
mg/m2	O
IV	O
bolus	O
given	O
over	O
2–4	O
minutes	O
,	O
followed	O
by	O
5-FU	other-medical
600	O
mg/m2	O
IV	O
infusion	O
in	O
500	O
mL	O
D5W	O
(	O
recommended	O
)	O
as	O
a	O
22-hour	O
continuous	O
infusion	O
.	O

The	O
most	O
potent	O
aphrodisiacs	other-medical
,	O
according	O
to	O
Levine	O
,	O
are	O
psychological	O
intimacy	O
and	O
voyeurism	O
:	O
``	O
looking	O
at	O
pictures	O
or	O
movies	O
of	O
people	O
engaged	O
in	O
genital	O
or	O
romantic	O
interplay	O
.	O
''	O

An	O
infusion	O
of	O
5-FU	other-medical
is	O
then	O
started	O
through	O
a	O
drip	O
or	O
pump	O
,	O
which	O
lasts	O
for	O
22	O
hours	O
.	O

Chlorpromazine	other-medical
may	O
be	O
used	O
as	O
an	O
antiemetic	O
in	O
dogs	O
and	O
cats	O
,	O
or	O
,	O
less	O
often	O
,	O
as	O
sedative	other-medical
prior	O
to	O
anesthesia	other-medical
.	O

A	O
study	O
observing	O
the	O
distribution	O
of	O
spermicide	O
containing	O
nonoxynol-9	other-medical
in	O
the	O
vaginal	O
tract	O
showed	O
“	O
After	O
10	O
min	O
the	O
gel	O
spread	O
within	O
the	O
vaginal	O
canal	O
providing	O
a	O
contiguous	O
covering	O
of	O
the	O
epithelium	O
of	O
variable	O
thickness.	O
”	O
The	O
sole	O
goal	O
of	O
spermicide	O
is	O
to	O
prevent	O
fertilization	O
.	O

It	O
is	O
almost	O
always	O
combined	O
with	O
an	O
estrogen	O
,	O
such	O
as	O
ethinylestradiol	other-medical
,	O
when	O
it	O
is	O
used	O
in	O
the	O
treatment	O
of	O
PCOS	O
in	O
women	O
.	O

Triclabendazole	other-medical
is	O
the	O
drug	O
of	O
choice	O
in	O
fasciolosis	O
,	O
as	O
it	O
is	O
highly	O
effective	O
against	O
both	O
mature	O
and	O
immature	O
flukes	O
.	O

In	O
November	O
2009	O
,	O
Mencia	O
began	O
appearing	O
in	O
commercials	O
for	O
a	O
weight-loss	O
product	O
called	O
Belly	other-medical
Burner	other-medical
,	O
which	O
he	O
has	O
claimed	O
to	O
have	O
used	O
personally	O
.	O

Naltrexone	other-medical
is	O
not	O
as	O
widely	O
used	O
as	O
buprenorphine	other-medical
or	O
methadone	other-medical
for	O
OUD	O
due	O
to	O
low	O
rates	O
of	O
patient	O
acceptance	O
,	O
non-adherence	O
due	O
to	O
daily	O
dosing	O
,	O
and	O
difficulty	O
achieving	O
abstinence	O
from	O
opioids	other-medical
before	O
beginning	O
treatment	O
.	O

Anthelmintic	other-medical
medicines	O
are	O
made	O
from	O
extracts	O
of	O
``	O
Leucaena	O
``	O
seeds	O
in	O
Sumatra	O
,	O
Indonesia	O
.	O

Large	O
amounts	O
of	O
heroin	other-medical
are	O
also	O
smuggled	O
throughout	O
the	O
(	O
Golden	O
Triangle	O
)	O
.	O

According	O
to	O
the	O
RCM	O
,	O
the	O
causal	O
effect	O
of	O
your	O
taking	O
or	O
not	O
taking	O
aspirin	other-medical
one	O
hour	O
ago	O
is	O
the	O
difference	O
between	O
how	O
your	O
head	O
would	O
have	O
felt	O
in	O
case	O
1	O
(	O
taking	O
the	O
aspirin	other-medical
)	O
and	O
case	O
2	O
(	O
not	O
taking	O
the	O
aspirin	other-medical
)	O
.	O

The	O
thiolactone	O
functional	O
group	O
is	O
also	O
present	O
in	O
some	O
pharmaceutical	O
drugs	O
such	O
as	O
citiolone	other-medical
and	O
erdosteine	other-medical
.	O

Fomivirsen	other-medical
(	O
brand	O
name	O
Vitravene	other-medical
)	O
is	O
an	O
antisense	O
antiviral	O
drug	O
that	O
was	O
used	O
in	O
the	O
treatment	O
of	O
cytomegalovirus	O
retinitis	O
(	O
CMV	O
)	O
in	O
immunocompromised	O
patients	O
,	O
including	O
those	O
with	O
AIDS	O
.	O

A	O
goitre	other-medical
may	O
have	O
one	O
nodule	other-medical
–	O
uninodular	other-medical
,	O
multiple	O
nodules	other-medical
–	O
multinodular	other-medical
,	O
or	O
be	O
diffuse	O
.	O

Thyroid	other-medical
nodules	other-medical
are	O
nodules	other-medical
(	O
raised	O
areas	O
of	O
tissue	O
or	O
fluid	O
)	O
which	O
commonly	O
arise	O
within	O
an	O
otherwise	O
normal	O
thyroid	O
gland	O
.	O

A	O
diuretic	other-medical
is	O
any	O
substance	O
that	O
promotes	O
the	O
production	O
of	O
urine	O
.	O

One	O
clinical	O
trial	O
of	O
ranibizumab	other-medical
for	O
age-related	O
macular	O
degeneration	O
administered	O
intravitreally	O
reported	O
intraocular	O
inflammation	O
rates	O
between	O
1.4	O
%	O
and	O
2.9	O
%	O
.	O

Probenecid	other-medical
inhibits	O
methotrexate	O
excretion	O
,	O
which	O
increases	O
the	O
risk	O
of	O
methotrexate	O
toxicity	O
.	O

Unlike	O
α2	O
adrenoceptor	O
agonists	O
such	O
as	O
guanfacine	other-medical
and	O
clonidine	other-medical
,	O
atomoxetine	other-medical
's	O
use	O
can	O
be	O
abruptly	O
stopped	O
without	O
significant	O
discontinuation	O
effects	O
being	O
seen	O
.	O

In	O
2007	O
,	O
as	O
part	O
of	O
a	O
six-member	O
committee	O
,	O
he	O
helped	O
to	O
negotiate	O
a	O
$	O
4.85	O
billion	O
settlement	O
between	O
Merck	O
and	O
nearly	O
27,000	O
patients	O
who	O
suffered	O
medical	O
problems	O
while	O
taking	O
Vioxx	other-medical
.	O

Its	O
most	O
major	O
brand	O
names	O
are	O
Provera	other-medical
as	O
oral	O
tablets	O
and	O
Depo-Provera	other-medical
as	O
an	O
aqueous	O
suspension	O
for	O
intramuscular	O
injection	O
.	O

A	O
large	O
cohort	O
study	O
of	O
babies	O
born	O
to	O
Israeli	O
women	O
exposed	O
to	O
metoclopramide	other-medical
during	O
pregnancy	O
found	O
no	O
evidence	O
that	O
the	O
drug	O
increases	O
the	O
risk	O
of	O
congenital	O
malformations	O
,	O
low	O
birth	O
weight	O
,	O
preterm	O
birth	O
,	O
or	O
perinatal	O
mortality	O
.	O

Another	O
type	O
of	O
immunotherapy	O
involves	O
vaccines	O
,	O
including	O
TroVax	other-medical
.	O

Biostrophin	other-medical
is	O
being	O
manufactured	O
by	O
Asklepios	O
BioPharmaceuticals	O
,	O
Inc	O
.	O
,	O
with	O
funding	O
provided	O
by	O
the	O
Muscular	O
Dystrophy	O
Association	O
.	O

Elway	O
had	O
LASIK	other-medical
eye	O
surgery	O
and	O
endorsed	O
Icon	O
LASIK	O
in	O
the	O
Denver	O
area	O
in	O
November	O
2008	O
.	O

In	O
addition	O
to	O
single-drug	O
formulations	O
,	O
MPA	other-medical
is	O
marketed	O
in	O
combination	O
with	O
the	O
estrogens	O
CEEs	other-medical
,	O
estradiol	O
,	O
and	O
estradiol	O
valerate	O
.	O

He	O
announced	O
the	O
importance	O
of	O
the	O
work	O
of	O
two	O
Bristol	O
colleagues	O
,	O
Frederick	O
Brittan	O
and	O
Joseph	O
Griffiths	O
Swayne	O
,	O
of	O
organisms	O
(	O
described	O
as	O
``	O
fungoid	O
``	O
)	O
in	O
the	O
``	O
rice-water	other-medical
evacuations	other-medical
``	O
of	O
cholera	O
victims	O
.	O

Leukotriene	other-medical
antagonists	other-medical
and	O
inhibitors	other-medical
(	O
montelukast	other-medical
,	O
zafirlukast	other-medical
,	O
and	O
zileuton	other-medical
)	O
often	O
are	O
helpful	O
in	O
treating	O
the	O
symptoms	O
of	O
AERD	O
.	O

Carbamazepine	other-medical
is	O
a	O
voltage-gated	O
sodium	O
channel	O
inhibitor	O
,	O
and	O
reduces	O
neuronal	O
excitability	O
by	O
preventing	O
depolarisation	O
.	O

Neurodevelopmental	O
outcome	O
of	O
prenatally	O
diagnosed	O
boys	O
with	O
47	O
,	O
XXY	O
(	O
Klinefelter	O
syndrome	O
)	O
and	O
the	O
potential	O
influence	O
of	O
early	other-medical
hormonal	other-medical
therapy	other-medical
(	O
EHT	other-medical
)	O
.	O

A	O
Chem-7	other-medical
is	O
thus	O
a	O
vital	O
tool	O
when	O
attempting	O
to	O
stabilize	O
a	O
patient	O
.	O

Since	O
then	O
,	O
FDA	O
has	O
determined	O
that	O
other	O
types	O
of	O
nitrosamine	O
compounds	O
,	O
e.g.	O
,	O
N-Nitrosodiethylamine	O
(	O
NDEA	O
)	O
,	O
are	O
present	O
at	O
unacceptable	O
levels	O
in	O
APIs	other-medical
from	O
multiple	O
API	other-medical
producers	O
of	O
valsartan	other-medical
and	O
other	O
drugs	O
in	O
the	O
ARB	other-medical
class	O
.	O
''	O

Immunodeficiency	other-medical
is	O
a	O
state	O
of	O
reduced	O
function	O
of	O
the	O
immune	O
system	O
,	O
which	O
can	O
be	O
caused	O
by	O
medical	O
conditions	O
or	O
treatments	O
.	O

Retinol	other-medical
is	O
a	O
form	O
of	O
vitamin	other-medical
A	other-medical
that	O
has	O
similar	O
but	O
milder	O
effects	O
and	O
is	O
present	O
in	O
many	O
over-the-counter	O
moisturizers	O
and	O
other	O
topical	O
products	O
.	O

However	O
,	O
ketoconazole	other-medical
has	O
largely	O
been	O
replaced	O
as	O
a	O
first-line	O
systemic	O
antifungal	other-medical
medication	O
by	O
other	O
azole	O
antifungal	O
agents	O
,	O
such	O
as	O
itraconazole	other-medical
,	O
because	O
of	O
ketoconazole	other-medical
's	O
greater	O
toxicity	O
,	O
poorer	O
absorption	O
,	O
and	O
more	O
limited	O
spectrum	O
of	O
activity	O
.	O

Tyrosine	other-medical
kinase	other-medical
(	O
a	O
subclass	O
of	O
protein	other-medical
kinases	other-medical
)	O
is	O
an	O
enzyme	other-medical
that	O
transfers	O
a	O
phosphate	other-medical
group	other-medical
from	O
an	O
ATP	other-medical
molecule	other-medical
to	O
a	O
protein	O
in	O
a	O
cell	O
.	O

The	O
Clinical	O
Pharmacogenetics	O
Implementation	O
Consortium	O
recommends	O
avoiding	O
amitriptyline	other-medical
in	O
patients	O
who	O
are	O
CYP2D6	O
ultrarapid	O
or	O
poor	O
metabolizers	O
,	O
due	O
to	O
the	O
risk	O
for	O
a	O
lack	O
of	O
efficacy	O
and	O
side	O
effects	O
,	O
respectively	O
.	O

With	O
a	O
strong	O
,	O
dense	O
smell	O
,	O
ether	other-medical
causes	O
irritation	O
to	O
respiratory	O
mucosa	O
and	O
is	O
uncomfortable	O
to	O
breathe	O
,	O
and	O
in	O
overdose	O
triggering	other-medical
salivation	other-medical
,	O
vomiting	other-medical
,	O
coughing	O
or	O
spasms	other-medical
.	O

After	O
treatment	O
of	O
a	O
high	O
risk	O
bleeding	O
ulcer	O
endoscopically	O
giving	O
a	O
PPI	other-medical
once	O
or	O
a	O
day	O
rather	O
than	O
as	O
an	O
infusion	O
appears	O
to	O
work	O
just	O
as	O
well	O
and	O
is	O
less	O
expensive	O
(	O
the	O
method	O
may	O
be	O
either	O
by	O
mouth	O
or	O
intravenously	O
)	O
.	O

Of	O
the	O
other	O
dose-dependent	O
side	O
effects	O
,	O
palpitations	O
(	O
4.5	O
%	O
at	O
10	O
mg	O
vs.	O
0.6	O
%	O
in	O
placebos	other-medical
)	O
and	O
flushing	O
(	O
2.6	O
%	O
vs.	O
0	O
%	O
)	O
occurred	O
more	O
often	O
in	O
women	O
;	O
dizziness	O
(	O
3.4	O
%	O
vs.	O
1.5	O
%	O
)	O
had	O
no	O
sex	O
bias	O
.	O

Many	O
BIG	O
studies	O
have	O
been	O
practice-changing	O
,	O
for	O
example	O
,	O
putting	O
aromatase	O
inhibitors	O
on	O
the	O
map	O
(	O
BIG	O
1-98	O
)	O
,	O
changing	O
how	O
we	O
treat	O
young	O
women	O
with	O
breast	O
cancer	O
(	O
SOFT	O
)	O
,	O
leading	O
to	O
a	O
major	O
breakthrough	O
in	O
treating	O
HER2-positive	O
breast	O
cancer	O
(	O
HERA	O
)	O
,	O
or	O
helping	O
physicians	O
evaluate	O
which	O
women	O
with	O
early	O
breast	O
cancer	O
could	O
be	O
spared	O
chemotherapy	other-medical
after	O
surgery	O
(	O
MINDACT	O
)	O
.	O

The	O
drug	O
was	O
originally	O
thought	O
to	O
function	O
as	O
a	O
kinase	other-medical
inhibitor	other-medical
but	O
was	O
subsequently	O
shown	O
to	O
be	O
an	O
Hsp90	other-medical
inhibitor	other-medical
where	O
it	O
uses	O
a	O
compact	O
conformation	O
to	O
insert	O
itself	O
into	O
the	O
ATP	O
binding	O
site	O
.	O

The	O
Australian	O
biotech	O
company	O
Giaconda	O
combines	O
bezafibrate	O
with	O
chenodeoxycholic	O
acid	O
in	O
an	O
anti-hepatitis	O
C	O
drug	O
combination	O
called	O
Hepaconda	other-medical
.	O

Triptans	other-medical
have	O
advantages	O
over	O
ergotamine	other-medical
and	O
dihydroergotamine	other-medical
,	O
such	O
as	O
selective	O
pharmacology	O
,	O
well	O
established	O
safety	O
record	O
and	O
evidence-based	O
prescribing	O
instructions	O
.	O

ART	other-medical
for	O
mothers	O
both	O
before	O
and	O
during	O
delivery	O
and	O
to	O
mothers	O
and	O
infants	O
after	O
delivery	O
are	O
recommended	O
to	O
substantially	O
reduce	O
the	O
risk	O
of	O
transmission	O
.	O

Estrogen	other-medical
treatment	other-medical
upregulates	O
TRPV6	O
transcripts	O
by	O
8-fold	O
in	O
VDR	O
KO	O
mice	O
and	O
by	O
4-fold	O
in	O
ovariectomized	O
mice	O
.	O

The	O
main	O
competitors	O
to	O
rosuvastatin	other-medical
are	O
atorvastatin	other-medical
and	O
simvastatin	other-medical
.	O

MPA	other-medical
is	O
marketed	O
under	O
a	O
large	O
number	O
of	O
brand	O
names	O
throughout	O
the	O
world	O
.	O

Adderall	other-medical
is	O
a	O
drug	O
that	O
affects	O
the	O
central	O
nervous	O
system	O
and	O
is	O
prescribed	O
to	O
individuals	O
with	O
attention	O
deficit	O
hyperactivity	O
disorder	O
(	O
ADHD	O
)	O
and/or	O
narcolepsy	O
.	O

An	O
orally	other-medical
disintegrating	other-medical
tablet	other-medical
or	O
orally	other-medical
dissolving	other-medical
tablet	other-medical
(	O
ODT	other-medical
)	O
is	O
a	O
drug	O
dosage	O
form	O
available	O
for	O
a	O
limited	O
range	O
of	O
over-the-counter	other-medical
(	O
OTC	other-medical
)	O
and	O
prescription	O
medications	O
.	O

The	O
ODT	other-medical
serves	O
as	O
an	O
alternative	O
dosage	O
form	O
for	O
patients	O
who	O
experience	O
dysphagia	O
(	O
difficulty	O
in	O
swallowing	O
)	O
or	O
for	O
where	O
compliance	O
is	O
a	O
known	O
issue	O
and	O
therefore	O
an	O
easier	O
dosage	O
form	O
to	O
take	O
ensures	O
that	O
medication	O
is	O
taken	O
.	O

There	O
is	O
evidence	O
that	O
spironolactone	other-medical
may	O
block	O
voltage-dependent	O
Ca2+	O
channels	O
.	O

In	O
2020	O
,	O
Baszucki	O
funded	O
a	O
study	O
on	O
the	O
effect	O
of	O
Hydroxychloroquine	other-medical
on	O
COVID-19	O
,	O
which	O
showed	O
no	O
evidence	O
of	O
it	O
preventing	O
or	O
treating	O
the	O
virus	O
.	O

On	O
November	O
14	O
,	O
it	O
was	O
revealed	O
that	O
the	O
DEA	O
had	O
intercepted	O
a	O
package	O
of	O
fifty	O
HGH	other-medical
syringes	O
en	O
route	O
to	O
Guillén	O
's	O
house	O
.	O

On	O
October	O
29	O
,	O
2014	O
Health	O
Canada	O
gave	O
the	O
permission	O
for	O
Sanofi	O
to	O
resume	O
production	O
of	O
BCG	other-medical
.	O

Caffeine	other-medical
is	O
a	O
substrate	O
for	O
CYP1A2	O
,	O
and	O
interacts	O
with	O
many	O
substances	O
through	O
this	O
and	O
other	O
mechanisms	O
.	O

Chronic	O
users	O
of	O
paracetamol	other-medical
may	O
have	O
a	O
higher	O
risk	O
of	O
developing	O
blood	O
cancer	O
.	O

Strontium	other-medical
ranelate	other-medical
stimulates	O
the	O
calcium-sensing	O
receptors	O
and	O
leads	O
to	O
the	O
differentiation	O
of	O
pre-osteoblast	O
to	O
osteoblast	O
which	O
increases	O
the	O
bone	O
formation	O
.	O

The	O
label	O
states	O
,	O
``	O
When	O
pregnancy	O
is	O
detected	O
,	O
discontinue	O
Zestril	other-medical
as	O
soon	O
as	O
possible	O
.	O
''	O

Plantar	O
warts	O
are	O
not	O
prevented	O
by	O
inoculation	O
with	O
HPV	other-medical
vaccines	O
because	O
the	O
warts	O
are	O
caused	O
by	O
different	O
strains	O
of	O
HPV	other-medical
.	O

Bufotalin	O
is	O
part	O
of	O
Ch'an	other-medical
Su	other-medical
,	O
a	O
traditional	O
Chinese	O
medicine	O
used	O
for	O
cancer	O
.	O

The	O
autoimmune	O
role	O
of	O
anti-GM1	other-medical
is	O
still	O
unclear	O
.	O

Acyclovir	other-medical
is	O
a	O
better	O
antiviral	O
because	O
it	O
shows	O
a	O
similar	O
effect	O
on	O
the	O
infection	O
as	O
vidarabine	other-medical
and	O
is	O
safer	O
to	O
use	O
in	O
neonates	O
.	O

Yuri	O
Larionov	O
stated	O
the	O
use	O
of	O
the	O
Furosemide	other-medical
was	O
for	O
weight	O
loss	O
but	O
diuretics	O
but	O
it	O
can	O
be	O
used	O
as	O
a	O
masking	O
agent	O
for	O
the	O
use	O
other	O
substances	O
,	O
Though	O
he	O
claims	O
that	O
``	O
during	O
the	O
month	O
of	O
December	O
he	O
had	O
bought	O
and	O
then	O
took	O
a	O
over-the-counter	O
drug	O
which	O
behind	O
his	O
back	O
contained	O
a	O
banned	O
matter	O
''	O

``	O
First	O
described	O
by	O
Arocha-Pinango	O
and	O
Layrisse	O
in	O
Venezuela	O
in	O
1967	O
,	O
the	O
hemorrhagic	O
diathesis	O
caused	O
in	O
humans	O
by	O
touching	O
the	O
``	O
Lonomia	O
``	O
species	O
begins	O
with	O
inflammatory	O
changes	O
at	O
the	O
site	O
of	O
envenoming	O
,	O
followed	O
by	O
systemic	O
symptoms	O
such	O
as	O
headache	other-medical
,	O
fever	other-medical
,	O
vomiting	other-medical
,	O
and	O
malaise	other-medical
.	O

In	O
this	O
capacity	O
he	O
was	O
involved	O
in	O
the	O
very	O
earliest	O
assessment	O
of	O
the	O
use	O
of	O
Penicillin	other-medical
in	O
war	O
wounds	O
.	O

However	O
,	O
gossypol	other-medical
also	O
had	O
serious	O
flaws	O
.	O

A	O
D	other-medical
&	other-medical
amp	other-medical
;	other-medical
C	other-medical
may	O
be	O
performed	O
early	O
in	O
pregnancy	O
to	O
remove	O
pregnancy	O
tissue	O
,	O
either	O
in	O
the	O
case	O
of	O
a	O
non-viable	O
pregnancy	O
,	O
such	O
as	O
a	O
missed	O
or	O
incomplete	O
miscarriage	O
,	O
or	O
an	O
undesired	O
pregnancy	O
,	O
as	O
in	O
a	O
surgical	O
abortion	O
.	O

Like	O
other	O
NSAIDs	other-medical
,	O
it	O
works	O
by	O
inhibiting	O
the	O
production	O
of	O
prostaglandins	O
by	O
decreasing	O
the	O
activity	O
of	O
the	O
enzyme	O
cyclooxygenase	O
(	O
COX	O
)	O
.	O

Cocaine	other-medical
is	O
the	O
only	O
local	O
anesthetic	O
that	O
also	O
produces	O
vasoconstriction	O
,	O
making	O
it	O
ideal	O
for	O
controlling	O
nosebleeds	O
.	O

The	O
authors	O
of	O
the	O
American	O
College	O
of	O
Chest	O
Physicians	O
Updates	O
on	O
Cough	O
Guidelines	O
(	O
2006	O
)	O
recommend	O
that	O
,	O
for	O
cough	O
associated	O
with	O
the	O
common	O
cold	O
,	O
first-generation	O
antihistamine-decongestants	other-medical
are	O
more	O
effective	O
than	O
newer	O
,	O
non-sedating	other-medical
antihistamines	other-medical
.	O

Tolerance	O
to	O
the	O
anticonvulsant	O
effects	O
of	O
clonazepam	other-medical
occurs	O
in	O
both	O
animals	O
and	O
humans	O
.	O

Josef	O
Jadassohn	O
described	O
the	O
first	O
case	O
of	O
metal	O
contact	O
dermatitis	O
in	O
1895	O
,	O
to	O
a	O
mercurial	O
-based	O
therapeutic	O
cream	O
,	O
and	O
confirmed	O
the	O
cause	O
by	O
epi-cutaneous	other-medical
patch	other-medical
testing	other-medical
.	O

Chemotherapy	other-medical
(	O
drug	O
treatment	O
for	O
cancer	O
)	O
may	O
be	O
used	O
before	O
surgery	O
,	O
after	O
surgery	O
,	O
or	O
instead	O
of	O
surgery	O
for	O
those	O
cases	O
in	O
which	O
surgery	O
is	O
considered	O
unsuitable	O
.	O

In	O
October	O
2010	O
FDA	O
notified	O
consumers	O
that	O
``	O
Slimming	O
Beauty	O
Bitter	O
Orange	O
Slimming	O
Capsules	O
contain	O
the	O
active	O
pharmaceutical	O
ingredient	O
sibutramine	other-medical
,	O
a	O
prescription-only	O
drug	O
which	O
is	O
a	O
stimulant	O
.	O

According	O
to	O
the	O
CDC	O
,	O
tighter	O
prescription	O
policies	O
by	O
doctors	O
did	O
not	O
necessarily	O
lead	O
to	O
this	O
increased	O
heroin	other-medical
use	O
.	O

One	O
study	O
found	O
approximately	O
15	O
%	O
of	O
chronic	O
MDMA	O
users	O
met	O
the	O
DSM-IV	other-medical
diagnostic	O
criteria	O
for	O
substance	O
dependence	O
.	O

The	O
Mexican	O
traveller	O
was	O
also	O
discharged	O
after	O
treatment	O
with	O
the	O
antiviral	O
drug	O
Tamiflu	other-medical
and	O
the	O
Centre	O
for	O
Health	O
Protection	O
confirmed	O
that	O
he	O
was	O
no	O
longer	O
carrying	O
the	O
virus	O
.	O

Pharmacological	O
studies	O
point	O
to	O
alterations	O
in	O
dopamine	other-medical
function	O
and	O
the	O
endocannabinoid	other-medical
system	O
.	O

Salicylic	other-medical
acid	other-medical
as	O
a	O
medication	O
is	O
used	O
most	O
commonly	O
to	O
help	O
remove	O
the	O
outer	O
layer	O
of	O
the	O
skin	O
.	O

Hunt	O
and	O
Liddy	O
met	O
with	O
a	O
CIA	O
operative	O
and	O
discussed	O
methods	O
of	O
assassinating	O
Anderson	O
,	O
which	O
included	O
covering	O
Anderson	O
's	O
car	O
steering	O
wheel	O
with	O
LSD	other-medical
to	O
drug	O
him	O
and	O
cause	O
a	O
fatal	O
accident	O
,	O
poisoning	O
his	O
aspirin	O
bottle	O
,	O
and	O
staging	O
a	O
fatal	O
robbery	O
.	O

Trientine	other-medical
dihydrochloride	other-medical
(	O
brand	O
name	O
Cufence	other-medical
)	O
was	O
approved	O
for	O
medical	O
use	O
in	O
the	O
European	O
Union	O
in	O
July	O
2019	O
.	O

To	O
move	O
towards	O
international	O
standards	O
,	O
the	O
Breeders	O
'	O
Cup	O
decided	O
to	O
eliminate	O
the	O
use	O
of	O
Lasix	other-medical
in	O
the	O
Juvenile	O
races	O
,	O
with	O
the	O
intention	O
of	O
extending	O
the	O
ban	O
to	O
other	O
races	O
in	O
subsequent	O
years	O
.	O

Upon	O
his	O
return	O
in	O
1951	O
,	O
Crosby	O
established	O
both	O
the	O
hematology	other-medical
and	O
oncology	other-medical
specialties	O
at	O
Walter	O
Reed	O
Army	O
Hospital	O
a	O
position	O
he	O
would	O
hold	O
until	O
1965	O
.	O

It	O
also	O
lists	O
possible	O
safety	O
concerns	O
:	O
``	O
Intake	O
of	O
3	O
grams	O
per	O
day	O
or	O
greater	O
of	O
omega-3	other-medical
fatty	O
acids	O
may	O
increase	O
the	O
risk	O
of	O
bleeding	O
,	O
although	O
there	O
is	O
little	O
evidence	O
of	O
significant	O
bleeding	O
risk	O
at	O
lower	O
doses	O
.	O

In	O
people	O
with	O
suspected	O
ketosis-prone	O
type	O
2	O
diabetes	O
,	O
determination	O
of	O
antibodies	O
against	O
glutamic	O
acid	O
decarboxylase	O
and	O
islet	O
cells	O
may	O
aid	O
in	O
the	O
decision	O
whether	O
to	O
continue	O
insulin	other-medical
administration	O
long-term	O
(	O
if	O
antibodies	O
are	O
detected	O
)	O
,	O
or	O
whether	O
to	O
withdraw	O
insulin	other-medical
and	O
attempt	O
treatment	O
with	O
oral	O
medication	O
as	O
in	O
type	O
2	O
diabetes	O
.	O

Substance	O
abuse	O
is	O
attributed	O
to	O
the	O
previously	O
damaged	O
relationship	O
between	O
Ward	O
and	O
Bonz	O
,	O
who	O
often	O
mentioned	O
marijuana	other-medical
in	O
the	O
band	O
's	O
live	O
shows	O
.	O

The	O
release	O
of	O
OxyContin	other-medical
in	O
1996	O
was	O
accompanied	O
by	O
an	O
aggressive	O
marketing	O
campaign	O
promoting	O
the	O
use	O
of	O
opioids	other-medical
for	O
pain	O
relief	O
.	O

It	O
was	O
the	O
first	O
second-generation	O
NSAA	other-medical
to	O
be	O
introduced	O
.	O

He	O
moved	O
to	O
London	O
where	O
he	O
became	O
a	O
surgeon	O
,	O
specialising	O
in	O
abdominal	other-medical
surgery	other-medical
,	O
at	O
the	O
London	O
Hospital	O
in	O
the	O
late	O
19th	O
and	O
early	O
20th	O
century	O
.	O

His	O
widow	O
,	O
Elaine	O
Joyce	O
,	O
stated	O
on	O
the	O
Sally	O
Jessy	O
Raphael	O
talk	O
show	O
that	O
Van	O
suffered	O
13	O
days	O
of	O
headaches	O
and	O
went	O
to	O
the	O
hospital	O
where	O
they	O
made	O
a	O
small	O
incision	O
and	O
tested	O
the	O
tumor	other-medical
.	O

Paramedics	O
responded	O
and	O
injected	O
the	O
turtle	O
with	O
Valium	other-medical
after	O
the	O
turtle	O
refused	O
to	O
let	O
go	O
of	O
the	O
woman	O
's	O
lip	O
.	O

Bevacizumab	other-medical
,	O
another	O
medication	O
for	O
the	O
same	O
purpose	O
,	O
resulted	O
in	O
an	O
incidence	O
between	O
0.09	O
%	O
and	O
0.4	O
%	O
.	O

A	O
phase	O
three	O
clinical	O
trial	O
found	O
that	O
Ribocyclib	other-medical
administered	O
in	O
combination	O
with	O
letrozole	other-medical
increased	O
the	O
likelihood	O
of	O
progression	O
free	O
survival	O
to	O
63	O
%	O
in	O
the	O
first	O
18	O
months	O
of	O
therapy	O
versus	O
42	O
%	O
for	O
letrozole	other-medical
alone	O
.	O

Acute	O
kidney	O
disease	O
is	O
now	O
termed	O
acute	other-medical
kidney	other-medical
injury	other-medical
and	O
is	O
marked	O
by	O
the	O
sudden	O
reduction	O
in	O
kidney	O
function	O
over	O
seven	O
days	O
.	O

The	O
combination	O
of	O
paracetamol	other-medical
with	O
caffeine	other-medical
is	O
superior	O
to	O
paracetamol	other-medical
alone	O
for	O
the	O
treatment	O
of	O
common	O
pain	O
conditions	O
,	O
including	O
dental	O
pain	O
,	O
``	O
post	O
partum	O
''	O
pain	O
,	O
and	O
headache	O
.	O

Constipation	other-medical
is	O
common	O
.	O

Transurethral	other-medical
injection	other-medical
of	O
bulking	O
agents	O
have	O
little	O
role	O
in	O
the	O
management	O
of	O
post-prostatecromy	O
incontinence	O
and	O
there	O
is	O
weak	O
evidence	O
that	O
these	O
agents	O
can	O
offer	O
any	O
improvement	O
.	O

Topical	O
corticosteroids	other-medical
are	O
not	O
effective	O
as	O
treatment	O
for	O
LET	O
,	O
but	O
many	O
will	O
respond	O
to	O
chloroquine	other-medical
.	O

Cetuximab	other-medical
and	O
other	O
EGFR	other-medical
inhibitors	other-medical
only	O
work	O
on	O
tumors	O
in	O
which	O
KRAS	O
is	O
not	O
mutated	O
.	O

Traditionally	O
quinquinas	O
contain	O
cinchona	O
bark	O
,	O
which	O
provides	O
quinine	other-medical
.	O

Whereas	O
other	O
TCAs	other-medical
are	O
useful	O
for	O
treating	O
insomnia	O
,	O
desipramine	O
can	O
cause	O
insomnia	O
as	O
a	O
side	O
effect	O
due	O
to	O
its	O
activating	O
properties	O
.	O

Until	O
2010	O
paracetamol	other-medical
was	O
believed	O
safe	O
in	O
pregnancy	O
however	O
,	O
in	O
a	O
study	O
published	O
in	O
October	O
2010	O
it	O
has	O
been	O
linked	O
to	O
infertility	O
in	O
the	O
adult	O
life	O
of	O
the	O
unborn	O
.	O

However	O
,	O
Tim	O
admitted	O
to	O
using	O
the	O
prescription	O
drug	O
Adderall	other-medical
five	O
days	O
prior	O
to	O
the	O
event	O
;	O
Adderall	other-medical
is	O
a	O
drug	O
banned	O
by	O
the	O
Nevada	O
State	O
Athletic	O
Commission	O
.	O

Petacchi	O
had	O
a	O
certificate	O
to	O
use	O
salbutamol	other-medical
in	O
the	O
treatment	O
of	O
asthma	O
,	O
but	O
his	O
level	O
of	O
salbutamol	other-medical
was	O
extremely	O
high	O
.	O

Court	O
acknowledged	O
that	O
physical	O
efficacy	O
of	O
imatinib	other-medical
mesylate	O
in	O
beta	O
crystalline	O
form	O
is	O
enhanced	O
in	O
comparison	O
to	O
other	O
forms	O
and	O
that	O
the	O
beta	O
crystalline	O
form	O
of	O
imatinib	other-medical
mesylate	O
has	O
30	O
per	O
cent	O
increased	O
bioavailability	O
as	O
compared	O
to	O
imatinib	other-medical
in	O
free	O
base	O
form	O
.	O

The	O
impact	O
of	O
postural	O
yoga	O
on	O
physical	O
and	O
mental	O
health	O
has	O
been	O
a	O
topic	O
of	O
systematic	O
studies	O
,	O
with	O
evidence	O
that	O
regular	O
yoga	O
practice	O
yields	O
benefits	O
for	O
low	O
back	other-medical
pain	other-medical
and	O
stress	other-medical
.	O

This	O
includes	O
methotrexate	other-medical
for	O
juvenile	O
idiopathic	O
arthritis	O
and	O
sumatriptan	other-medical
for	O
treatment	O
of	O
migraines	O
.	O

In	O
2010	O
,	O
Schulten	O
's	O
group	O
at	O
Illinois	O
and	O
researchers	O
at	O
the	O
University	O
of	O
Utah	O
published	O
research	O
examining	O
the	O
development	O
of	O
drug	O
resistance	O
to	O
Tamiflu	other-medical
in	O
H1N1pdm	O
swine	O
influenza	O
and	O
H5N1	O
avian	O
influenza	O
virus	O
.	O

Gemzar	other-medical
is	O
commonly	O
used	O
in	O
the	O
treatment	O
of	O
pancreatic	O
cancer	O
,	O
usually	O
in	O
coordination	O
with	O
5-FU	other-medical
chemotherapy	O
and	O
radiology	O
.	O

In	O
the	O
late	O
2000s	O
,	O
reports	O
in	O
the	O
Israeli	O
media	O
claimed	O
that	O
injections	O
of	O
long-acting	O
contraceptive	O
Depo-Provera	other-medical
had	O
been	O
forced	O
on	O
hundreds	O
of	O
Ethiopian-Jewish	O
immigrants	O
both	O
in	O
transit	O
camps	O
in	O
Ethiopia	O
and	O
after	O
their	O
arrival	O
in	O
Israel	O
.	O

Salbutamol	other-medical
is	O
usually	O
used	O
with	O
an	O
inhaler	O
or	O
nebulizer	O
,	O
but	O
it	O
is	O
also	O
available	O
in	O
a	O
pill	O
,	O
liquid	O
,	O
and	O
intravenous	O
solution	O
.	O

The	O
WHO	O
stated	O
that	O
a	O
coronavirus	other-medical
vaccine	other-medical
could	O
be	O
ready	O
in	O
approximately	O
18	O
months	O
.	O

In	O
December	O
2014	O
,	O
Boulle	O
's	O
company	O
Tendyne	O
Holdings	O
Inc	O
.	O
announced	O
the	O
first	O
successful	O
human	O
Mitral	other-medical
Valve	other-medical
implant	other-medical
at	O
the	O
Royal	O
Brompton	O
Hospital	O
in	O
London	O
,	O
England	O
.	O

Between	O
2000	O
and	O
2014	O
there	O
was	O
an	O
``	O
alarming	O
increase	O
in	O
heroin	other-medical
use	O
across	O
the	O
country	O
and	O
an	O
epidemic	O
of	O
drug	O
overdose	O
deaths	O
''	O
.	O

Most	O
of	O
these	O
cases	O
are	O
now	O
thought	O
to	O
be	O
manifestation	O
of	O
tuberculosis	O
and	O
indeed	O
they	O
respond	O
well	O
to	O
anti-tuberculous	other-medical
treatment	other-medical
.	O

One	O
review	O
found	O
that	O
antivirals	O
(	O
such	O
as	O
aciclovir	other-medical
)	O
are	O
ineffective	O
in	O
improving	O
recovery	O
from	O
Bell	O
's	O
palsy	O
beyond	O
steroids	O
alone	O
in	O
mild	O
to	O
moderate	O
disease	O
.	O

Cyclophosphamide	other-medical
is	O
one	O
of	O
the	O
most	O
potent	O
immunosuppressive	O
substances	O
.	O

Generally	O
speaking	O
,	O
retinoids	other-medical
increase	O
the	O
skin	O
's	O
sensitivity	O
to	O
sunlight	O
and	O
are	O
therefore	O
recommended	O
for	O
use	O
at	O
night	O
.	O

Rabeprazole	other-medical
binds	O
to	O
cysteine	O
813	O
and	O
both	O
892	O
and	O
321	O
.	O

NSAIDs	other-medical
may	O
also	O
be	O
illegal	O
in	O
competition	O
,	O
so	O
it	O
may	O
be	O
necessary	O
to	O
stop	O
treatment	O
with	O
NSAIDs	other-medical
several	O
days	O
before	O
the	O
horse	O
competes	O
.	O

This	O
includes	O
providing	O
methadone	other-medical
for	O
addicts	O
as	O
well	O
as	O
providing	O
psychiatrists	O
,	O
nurses	O
,	O
and	O
case	O
works	O
,	O
additionally	O
the	O
program	O
``	O
also	O
provides	O
educational	O
programs	O
for	O
specific	O
patients	O
who	O
were	O
under	O
conditions	O
of	O
deferred	O
prosecution	O
.	O
''	O

Desquamation	other-medical
(	O
skin	O
peeling	O
)	O
can	O
occur	O
with	O
severe	O
mercury	O
poisoning	O
acquired	O
by	O
handling	O
elemental	O
mercury	O
.	O

A	O
beneficial	O
side	O
effect	O
of	O
tamoxifen	other-medical
is	O
that	O
it	O
prevents	O
bone	O
loss	O
by	O
acting	O
as	O
an	O
ER	O
agonist	O
(	O
i.e.	O
,	O
mimicking	O
the	O
effects	O
of	O
estrogen	O
)	O
in	O
this	O
cell	O
type	O
.	O

The	O
mode	O
of	O
delivery	O
is	O
also	O
important	O
,	O
with	O
a	O
planned	O
Caesarian	other-medical
section	other-medical
having	O
a	O
lower	O
risk	O
than	O
vaginal	O
delivery	O
or	O
emergency	O
Caesarian	other-medical
section	other-medical
.	O

More	O
severe	O
eruptions	O
usually	O
clear	O
up	O
after	O
treatment	O
for	O
one	O
to	O
three	O
months	O
with	O
Accutane	other-medical
or	O
tetracycline	other-medical
.	O

IVF	other-medical
is	O
available	O
for	O
women	O
aged	O
18	O
to	O
45	O
.	O

Antitumor	O
drugs	O
targeting	O
this	O
section	O
of	O
Hsp90	O
include	O
the	O
antibiotics	O
geldanamycin	other-medical
,	O
herbimycin	other-medical
,	O
radicicol	other-medical
,	O
deguelin	other-medical
,	O
derrubone	other-medical
,	O
macbecin	other-medical
,	O
and	O
beta-lactams	other-medical
.	O

Fame	O
was	O
gained	O
by	O
the	O
resident	O
of	O
the	O
house	O
,	O
doctor	O
Gurari	O
Fabian	O
Natanovich	O
who	O
treated	O
skin	O
and	O
internal	O
diseases	O
X-rays	other-medical
.	O

Benzopyrone	other-medical
may	O
refer	O
to	O
either	O
of	O
two	O
ketone	O
derivatives	O
of	O
benzopyran	O
which	O
constitute	O
the	O
core	O
skeleton	O
of	O
many	O
flavonoid	O
compounds	O
:	O

Dermatologic	O
conditions	O
cause	O
about	O
75	O
%	O
of	O
cases	O
of	O
desquamative	O
gingivitis	O
,	O
and	O
over	O
95	O
%	O
of	O
the	O
dermatologic	O
cases	O
are	O
accounted	O
for	O
by	O
either	O
oral	other-medical
lichen	other-medical
planus	other-medical
or	O
cicatricial	other-medical
pemphigoid	other-medical
.	O

Palliative	other-medical
care	other-medical
specialists	O
can	O
help	O
with	O
physical	O
symptoms	O
,	O
emotional	O
factors	O
such	O
as	O
loss	O
of	O
function	O
and	O
jobs	O
,	O
depression	O
,	O
fear	O
,	O
and	O
existential	O
concerns	O
.	O

In	O
humans	O
5-HTP	O
has	O
never	O
been	O
clinically	O
associated	O
with	O
serotonin	O
syndrome	O
,	O
although	O
a	O
case	O
report	O
suggests	O
5-HTP	O
can	O
precipitate	O
mania	O
when	O
added	O
to	O
an	O
MAOI	other-medical
.	O

Hydrocodone	other-medical
,	O
almost	O
as	O
potent	O
as	O
oxycodone	other-medical
,	O
in	O
combined	O
form	O
previously	O
allowed	O
refills	O
.	O

Lansoprazole	other-medical
reacts	O
with	O
cysteine	O
813	O
and	O
cysteine	O
321	O
,	O
whereas	O
pantoprazole	other-medical
and	O
tenatoprazole	other-medical
react	O
with	O
cysteine	O
813	O
and	O
822	O
.	O

These	O
secondary	O
ingredients	O
are	O
not	O
mainstream	O
in	O
the	O
United	O
States	O
,	O
where	O
nonoxynol-9	other-medical
alone	O
is	O
typical	O
.	O

Fluvoxamine	other-medical
was	O
the	O
first	O
SSRI	other-medical
to	O
be	O
approved	O
in	O
Japan	O
(	O
1999	O
)	O
sertraline	other-medical
received	O
approval	O
in	O
April	O
2006	O
,	O
having	O
been	O
pending	O
approval	O
for	O
over	O
15	O
years	O
.	O

Transdermal	other-medical
estradiol	other-medical
patches	other-medical
are	O
described	O
as	O
delivering	O
a	O
fixed	O
amount	O
of	O
estradiol	O
such	O
as	O
50	O
µg/day	O
or	O
100	O
µg/day	O
.	O

The	O
typical	O
course	O
of	O
isotretinoin	other-medical
treatment	O
will	O
last	O
4–5	O
months	O
,	O
and	O
is	O
generally	O
considered	O
to	O
be	O
an	O
option	O
when	O
nothing	O
else	O
has	O
worked	O
.	O

The	O
US	O
National	O
Institutes	O
of	O
Health	O
lists	O
three	O
conditions	O
for	O
which	O
fish	other-medical
oil	other-medical
and	O
other	O
omega-3	other-medical
sources	O
are	O
most	O
highly	O
recommended	O
:	O
hypertriglyceridemia	O
(	O
high	O
triglyceride	O
level	O
)	O
,	O
preventing	O
secondary	O
cardiovascular	O
disease	O
,	O
and	O
hypertension	O
(	O
high	O
blood	O
pressure	O
)	O
.	O

The	O
same	O
study	O
showed	O
taking	O
potassium	other-medical
supplements	other-medical
during	O
gossypol	other-medical
treatment	O
did	O
not	O
prevent	O
hypokalemia	O
in	O
primates	O
.	O

In	O
the	O
1940s	O
and	O
1950s	O
,	O
reports	O
began	O
to	O
emerge	O
about	O
the	O
recreational	O
use	O
of	O
Benzedrine	other-medical
inhalers	other-medical
,	O
and	O
in	O
1949	O
,	O
doctors	O
began	O
to	O
move	O
away	O
from	O
prescribing	O
Benzedrine	other-medical
as	O
a	O
bronchodilator	other-medical
and	O
appetite	O
suppressant	O
.	O

Other	O
NSAIDs	other-medical
,	O
though	O
once	O
used	O
to	O
treat	O
Dressler	O
syndrome	O
,	O
are	O
less	O
advocated	O
and	O
should	O
be	O
avoided	O
in	O
patients	O
with	O
ischemic	O
heart	O
disease	O
.	O

Insulin	other-medical
resistance	O
reduces	O
the	O
body	O
's	O
sensitivity	O
to	O
insulin	other-medical
.	O

FKBP	O
(	O
FKBP1A	O
)	O
does	O
not	O
normally	O
form	O
a	O
dimer	O
but	O
will	O
dimerize	O
in	O
the	O
presence	O
of	O
FK1012	other-medical
,	O
a	O
derivative	O
of	O
the	O
drug	O
tacrolimus	other-medical
(	O
FK506	other-medical
)	O
.	O

Niacin	other-medical
has	O
also	O
been	O
used	O
and	O
tested	O
for	O
the	O
purpose	O
of	O
enhancing	O
detoxification	other-medical
by	O
removing	O
skin	O
lipid-stored	O
xenobiotics	other-medical
.	O

These	O
children	O
had	O
respiratory	O
tract	O
infections	O
at	O
the	O
time	O
the	O
specimens	O
were	O
collected	O
(	O
in	O
one	O
girl	O
so	O
severe	O
that	O
mechanical	other-medical
ventilation	other-medical
was	O
needed	O
)	O
,	O
while	O
testing	O
negative	O
for	O
other	O
causes	O
like	O
Human	O
respiratory	O
syncytial	O
virus	O
(	O
RSV	O
)	O
,	O
parainfluenza	O
virus	O
es	O
(	O
types	O
1–3	O
)	O
,	O
influenza	O
A	O
and	O
B	O
viruses	O
,	O
and	O
adenovirus	O
by	O
direct	O
immunofluorescence	O
assay	O
as	O
well	O
as	O
human	O
metapneumovirus	O
and	O
HCoV-NH	O
by	O
reverse	O
transcription	O
polymerase	O
chain	O
reaction	O
(	O
RT-PCR	O
)	O
.	O

The	O
MHA-TP	other-medical
test	O
detects	O
antibodies	O
to	O
the	O
bacteria	O
that	O
cause	O
syphilis	O
and	O
can	O
be	O
used	O
to	O
detect	O
syphilis	O
in	O
all	O
stages	O
,	O
except	O
during	O
the	O
first	O
3	O
to	O
4	O
weeks	O
.	O

Spirorenone	other-medical
(	O
INN	other-medical
)	O
(	O
developmental	O
code	O
name	O
ZK-35973	other-medical
)	O
is	O
a	O
steroidal	O
antimineralocorticoid	O
of	O
the	O
spirolactone	O
group	O
that	O
was	O
never	O
marketed	O
.	O

Complement	other-medical
dysfunction	other-medical
may	O
predispose	O
some	O
patients	O
to	O
bacterial	other-medical
infections	other-medical
.	O

The	O
efficacy	O
of	O
fluoxetine	other-medical
in	O
the	O
treatment	O
of	O
panic	O
disorder	O
was	O
demonstrated	O
in	O
two	O
12-week	O
randomized	O
multicenter	O
phase	O
III	O
clinical	O
trials	O
that	O
enrolled	O
patients	O
diagnosed	O
with	O
panic	O
disorder	O
,	O
with	O
or	O
without	O
agoraphobia	O
.	O

This	O
same	O
amount	O
of	O
potassium	other-medical
chloride	other-medical
would	O
do	O
no	O
harm	O
if	O
taken	O
orally	O
and	O
not	O
injected	O
directly	O
into	O
the	O
blood	O
.	O

The	O
two	O
contraindications	O
to	O
taking	O
ezetimibe	other-medical
are	O
a	O
previous	O
allergic	O
reaction	O
to	O
it	O
,	O
including	O
symptoms	O
of	O
rash	O
,	O
angioedema	O
,	O
and	O
anaphylaxis	O
,	O
and	O
severe	O
liver	O
disease	O
,	O
especially	O
when	O
taken	O
with	O
a	O
statin	O
.	O

Evidence	O
of	O
the	O
effects	O
of	O
terrestrial	O
forms	O
of	O
ionizing	O
radiation	O
on	O
the	O
CNS	other-medical
has	O
been	O
documented	O
from	O
radiotherapy	O
patients	O
,	O
although	O
the	O
dose	O
is	O
higher	O
for	O
these	O
patients	O
than	O
would	O
be	O
experienced	O
by	O
astronauts	O
in	O
the	O
space	O
environment	O
.	O

She	O
is	O
shown	O
being	O
given	O
Electroconvulsive	other-medical
therapy	other-medical
(	O
ECT	other-medical
)	O
as	O
a	O
clinical	O
treatment	O
and	O
being	O
discussed	O
at	O
a	O
lecture	O
for	O
medical	O
students	O
.	O

The	O
FDA	O
approved	O
reslizumab	O
(	O
US	O
trade	O
name	O
Cinqair	other-medical
)	O
for	O
use	O
with	O
other	O
asthma	other-medical
medicines	other-medical
for	O
the	O
maintenance	O
treatment	O
of	O
severe	O
asthma	O
in	O
patients	O
aged	O
18	O
years	O
and	O
older	O
on	O
23	O
March	O
2016	O
.	O

The	O
virus	O
isolated	O
in	O
the	O
2009	O
outbreak	O
have	O
been	O
found	O
resistant	O
to	O
amantadine	other-medical
and	O
rimantadine	other-medical
.	O

The	O
adverse	O
effects	O
of	O
mechlorethamine	other-medical
depend	O
on	O
the	O
formulation	O
.	O

There	O
are	O
also	O
nootropic	O
drugs	O
such	O
as	O
the	O
common	O
racetams	other-medical
Piracetam	other-medical
and	O
Noopept	other-medical
(	O
O	O
mberaceta	other-medical
m	O
)	O
along	O
with	O
the	O
neuroprotective	O
Semax	O
,	O
and	O
N-Acetyl	O
Semax	O
.	O

Acetazolamide	other-medical
also	O
helps	O
prevent	O
the	O
condition	O
.	O

Oxaliplatin	other-medical
by	O
itself	O
has	O
modest	O
activity	O
against	O
advanced	O
colorectal	O
cancer	O
.	O

Ketazolam	other-medical
breaks	O
down	O
in	O
the	O
blood	O
to	O
diazepam	other-medical
which	O
breaks	O
down	O
to	O
demoxepam	other-medical
which	O
breaks	O
down	O
to	O
desmethyldiazepam	O
.	O

Muhtar	O
studied	O
histology	O
in	O
Louis-Charles	O
Malassez	O
’	O
s	O
laboratory	O
and	O
pathological	other-medical
anatomy	other-medical
in	O
Hôpital	O
de	O
la	O
Charité	O
from	O
P.C.E	O
.	O

Symptoms	O
of	O
an	O
allergic	other-medical
reaction	other-medical
include	O
rash	other-medical
,	O
itching	other-medical
,	O
swelling	other-medical
,	other-medical
severe	other-medical
dizziness	other-medical
,	O
and	O
trouble	O
breathing	O
.	O

The	O
law	O
enforcement	O
duties	O
involve	O
counter-	O
narcotic	other-medical
operations	O
,	O
fisheries	O
,	O
and	O
environmental	O
protection	O
.	O

In	O
2011	O
,	O
their	O
son	O
Andrew	O
died	O
of	O
an	O
OxyContin	other-medical
overdose	O
at	O
the	O
now-closed	O
Sunset	O
Plaza	O
Drive	O
sober	O
living	O
facility	O
in	O
California	O
.	O

As	O
such	O
,	O
as	O
tramadol	other-medical
is	O
related	O
to	O
venlafaxine	other-medical
,	O
the	O
same	O
conditions	O
apply	O
.	O

URL	O
Pharma	O
raised	O
the	O
price	O
from	O
$	O
0.09	O
per	O
tablet	O
to	O
$	O
4.85	O
,	O
and	O
the	O
FDA	O
removed	O
the	O
older	O
unapproved	O
colchicine	other-medical
from	O
the	O
market	O
in	O
October	O
2010	O
,	O
both	O
in	O
oral	O
and	O
intravenous	O
forms	O
,	O
but	O
gave	O
pharmacies	O
the	O
opportunity	O
to	O
buy	O
up	O
the	O
older	O
unapproved	O
colchicine	other-medical
.	O

Lamivudine	other-medical
showed	O
no	O
evidence	O
of	O
carcinogenicity	O
or	O
mutagenicity	O
in	O
``	O
in	O
vivo	O
''	O
studies	O
in	O
mice	O
and	O
rats	O
at	O
doses	O
from	O
10	O
to	O
58	O
times	O
those	O
used	O
in	O
humans	O
.	O

Cognitive	other-medical
behavioral	other-medical
therapy	other-medical
may	O
improve	O
quality	O
of	O
life	O
,	O
asthma	O
control	O
,	O
and	O
anxiety	O
levels	O
in	O
people	O
with	O
asthma	O
.	O

Most	O
subjects	O
recovered	O
after	O
stopping	O
treatment	O
and	O
taking	O
potassium	other-medical
supplements	other-medical
.	O

The	O
anticonvulsants	other-medical
carbamazepine	other-medical
and	O
oxcarbazepine	other-medical
are	O
especially	O
effective	O
in	O
trigeminal	O
neuralgia	O
.	O

It	O
confirmed	O
an	O
association	O
between	O
rosiglitazone	other-medical
and	O
an	O
increased	O
risk	O
of	O
heart	other-medical
failure	other-medical
and	O
fractures	other-medical
,	O
but	O
not	O
of	O
heart	other-medical
attack	other-medical
,	O
and	O
concluded	O
that	O
it	O
``	O
does	O
not	O
increase	O
the	O
risk	O
of	O
overall	O
cardiovascular	O
morbidity	O
or	O
mortality	O
compared	O
with	O
standard	O
glucose-lowering	O
drugs	O
.	O
''	O

Since	O
the	O
introduction	O
of	O
adjuvant	O
chemotherapy	O
,	O
chiefly	O
platinum-based	O
drugs	O
like	O
cisplatin	other-medical
and	O
carboplatin	other-medical
,	O
the	O
outlook	O
has	O
improved	O
substantially	O
.	O

Catatonia	O
with	O
inability	O
to	O
speak	O
is	O
responsive	O
to	O
lorazepam	other-medical
.	O

Adalimumab	other-medical
has	O
been	O
shown	O
to	O
reduce	O
the	O
signs	O
and	O
symptoms	O
of	O
moderate	O
to	O
severe	O
Crohn	O
's	O
disease	O
.	O

Levels	O
of	O
anti-GM1	other-medical
antibodies	O
are	O
elevated	O
in	O
patients	O
with	O
various	O
forms	O
of	O
dementia	O
.	O

The	O
results	O
of	O
a	O
preliminary	O
study	O
of	O
40	O
people	O
diagnosed	O
with	O
Major	O
Depressive	O
Disorder	O
suggests	O
that	O
routinely	O
engaging	O
in	O
expressive	O
writing	O
may	O
be	O
effective	O
in	O
reducing	O
symptoms	O
of	O
depression	other-medical
.	O

By	O
suppressing	O
the	O
production	O
of	O
melatonin	other-medical
over	O
the	O
course	O
of	O
the	O
night	O
rats	O
showed	O
increased	O
rates	O
of	O
tumors	O
over	O
the	O
course	O
of	O
a	O
four-week	O
period	O
.	O

However	O
,	O
in	O
this	O
case	O
the	O
parent	O
compound	O
does	O
not	O
have	O
the	O
side	O
effects	O
associated	O
with	O
terfenadine	O
,	O
and	O
so	O
both	O
loratadine	other-medical
and	O
its	O
active	O
metabolite	O
,	O
desloratadine	other-medical
,	O
are	O
currently	O
marketed	O
.	O

Quinine	other-medical
was	O
used	O
in	O
treating	O
malaria	O
.	O

One	O
of	O
the	O
most	O
popular	O
and	O
common	O
treatments	O
used	O
``	O
for	O
life-threatening	O
and	O
severe	O
ophthalmic	O
mycoses	O
''	O
is	O
amphotericin	other-medical
B	other-medical
which	O
is	O
a	O
specific	O
anti-fungal	O
drug	O
.	O

Amlodipine	other-medical
-association	O
edema	O
can	O
be	O
avoided	O
by	O
adding	O
[	O
[	O
ACE	other-medical
inhibitors	other-medical
]	O
]	O
or	O
angiotensin	other-medical
II	other-medical
receptor	other-medical
antagonist	other-medical
.	O

Treatment	O
may	O
include	O
a	O
direct	other-medical
thrombin	other-medical
inhibitor	other-medical
,	O
such	O
as	O
lepirudin	other-medical
or	O
argatroban	other-medical
.	O

Lamivudine	other-medical
treatment	O
has	O
been	O
shown	O
to	O
restore	O
zidovudine	other-medical
sensitivity	O
of	O
previously	O
resistant	O
HIV	O
.	O

He	O
founded	O
the	O
Paris	O
Medicine	O
Company	O
,	O
creating	O
and	O
producing	O
its	O
most	O
well-known	O
patent	O
medicine	O
products	O
,	O
Grove	other-medical
’	other-medical
s	other-medical
Tasteless	other-medical
Chill	other-medical
Tonic	other-medical
and	O
Laxative	other-medical
Bromo	other-medical
Quinine	other-medical
tablets	other-medical
.	O

An	O
elevated	O
EPL	O
or	O
LY30	O
suggests	O
fibrinolysis	O
and	O
may	O
be	O
treated	O
with	O
an	O
antifibrinolytic	O
,	O
such	O
as	O
tranexamic	other-medical
acid	other-medical
or	O
aminocaproic	other-medical
acid	other-medical
,	O
in	O
the	O
appropriate	O
clinical	O
setting	O
.	O

Nodules	other-medical
that	O
grow	O
larger	O
or	O
produce	O
symptoms	O
may	O
eventually	O
need	O
medical	O
care	O
.	O

The	O
center	O
is	O
for	O
adults	O
with	O
neurodevelopmental	other-medical
disorders	other-medical
complicated	O
by	O
cognitive	other-medical
dysfunction	other-medical
.	O

In	O
the	O
Brugada	O
syndrome	O
,	O
changes	O
may	O
be	O
found	O
in	O
the	O
resting	O
ECG	other-medical
with	O
evidence	O
of	O
right	O
bundle	O
branch	O
block	O
(	O
RBBB	O
)	O
and	O
ST	O
elevation	O
in	O
the	O
chest	O
leads	O
V1-V3	O
,	O
with	O
an	O
underlying	O
propensity	O
to	O
sudden	O
cardiac	O
death	O
.	O

However	O
,	O
it	O
is	O
important	O
to	O
note	O
that	O
high	O
doses	O
of	O
NSAIDs	other-medical
given	O
over	O
several	O
days	O
can	O
cause	O
kidney	O
damage	O
,	O
as	O
well	O
as	O
ulcers	O
.	O

Loratadine	other-medical
,	O
sold	O
under	O
the	O
brand	O
name	O
Claritin	other-medical
among	O
others	O
,	O
is	O
a	O
medication	O
used	O
to	O
treat	O
allergies	O
.	O

Because	O
the	O
R	O
value	O
on	O
the	O
TEG	other-medical
represents	O
the	O
time	O
it	O
takes	O
for	O
clot	O
formation	O
to	O
start	O
,	O
it	O
is	O
a	O
reflection	O
of	O
coagulation	O
factor	O
activity	O
.	O

Azerizin	other-medical
is	O
claimed	O
to	O
be	O
a	O
proprietary	O
blend	O
of	O
the	O
natural	O
ingredients	O
nicotinamide	O
,	O
azelaic	O
acid	O
,	O
quercetin	O
and	O
curcumin	O
that	O
purportedly	O
combine	O
the	O
anti-inflammatory	O
and	O
antimicrobial	O
properties	O
,	O
along	O
with	O
inhibiting	O
effects	O
on	O
sebum	O
production	O
.	O